Brought to you by 
Millennium acquires LeukoSite for $585mm
Nov 1999
Executive Summary
Millennium Pharmaceuticals has acquired LeukoSite (cancer, autoimmune, and inflammatory disease therapeutics) for about $585mm. Millennium has issued common stock worth about $33 (0.43 share) for each LeukoSite share; that's a (pr)62% premium to LeukoSite's market average.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Intra-Biotech Deal
- Payment Includes Stock
- Full Acquisition
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Millennium acquires LeukoSite for $585mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice